Treatment of malignant pheochromocytoma with a new radiopharmaceutical.
A new radiopharmaceutical, [131I]metaiodobenzylguandine, concentrates in some malignant pheochromocytomas. Five patients were treated with two to four doses of [131I]MIBG (99-197 mCi/dose). Two patients had substantial subjective and objective responses. [131I]MIBG is the first chemically synthesized radiopharmaceutical of complex molecular structure to reduce cancer.
D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000302:Adrenal Cortex / Q000502:physiology; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010673:Pheochromocytoma / Q000378:metabolism / Q000532:radiotherapy*; D013961:Thyroid Gland / Q000378:metabolism
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine